Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARDAMON study of CarCyDex with upfront ASCT and carfilzomib maintenance in untreated transplant-eligible multiple myeloma
2014-000506-35Phase 2Unknown
- Sponsor
- University College London
- Start
- Dec 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carfilzomib, cyclophosphamide and dexamethasone in multiple myeloma (MM), sponsored by University College London. Primary endpoint: Major response rate after 4 cycles of CarCyDex. Status: unknown.
02
Drugs
carfilzomibcyclophosphamidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2014-000506-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000506-35.